A Phase 4, 52-week (Primary Analysis at 24-weeks), Randomized, Stratified, Open-label, Active-controlled, Parallel-group, Effectiveness Study, Comparing FF/UMEC/VI With Non-ellipta Usual Care (ICS/LABA) in Adult Participants With Uncontrolled Asthma
Latest Information Update: 28 May 2025
At a glance
- Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary) ; Corticosteroids
- Indications Asthma
- Focus Therapeutic Use
- Acronyms PERFORM
- Sponsors GSK
Most Recent Events
- 21 May 2025 Planned primary completion date changed from 10 Nov 2025 to 1 Sep 2025.
- 17 Mar 2025 Planned primary completion date changed from 11 Mar 2026 to 10 Nov 2025.
- 17 Mar 2025 Status changed from recruiting to active, no longer recruiting.